BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 24.11 USD -2.74% Market Closed
Market Cap: 4.5B USD
Have any thoughts about
BridgeBio Pharma Inc?
Write Note

BridgeBio Pharma Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BridgeBio Pharma Inc
Total Current Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
BridgeBio Pharma Inc
NASDAQ:BBIO
Total Current Liabilities
$139.2m
CAGR 3-Years
13%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%

See Also

What is BridgeBio Pharma Inc's Total Current Liabilities?
Total Current Liabilities
139.2m USD

Based on the financial report for Sep 30, 2024, BridgeBio Pharma Inc's Total Current Liabilities amounts to 139.2m USD.

What is BridgeBio Pharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
28%

Over the last year, the Total Current Liabilities growth was 31%. The average annual Total Current Liabilities growth rates for BridgeBio Pharma Inc have been 13% over the past three years , 28% over the past five years .

Back to Top